UBP1

UBP1 (LBP-1a) is a sequence-specific DNA-binding transcription factor of the LSF/LBP-1 family that acts as a context-dependent activator or repressor and is required for extraembryonic vascular development (PMID:15282311, PMID:15716014, PMID:19384868). Its nuclear access is conditional: expressed alone it is confined to the cytosol, and only heterodimerization with the splice variant LBP-1b, which provides a nuclear localization signal, drives nuclear translocation, after which UBP1 accumulates at PML bodies via its N-terminal region (PMID:16115195). In the nucleus UBP1 directs distinct gene programs through direct DNA binding—occupying the PREX element upstream of the CYP2A8 gene to enhance its transcription (PMID:15716014) and binding immunoglobulin switch regions Smu and Salpha in an isotype-specific manner to repress class switch recombination, with loss of LSF/LBP-1 activity selectively increasing IgA switching (PMID:19384868). The direction of its regulatory output depends on promoter geometry: in a subcomplex with the Mediator subunit MED16 and TFCP2, UBP1 activates transcription when its binding motif lies proximal to the transcription start site but represses when the motif overlaps the start site, a mechanism that enforces HIV-1 latency by blocking preinitiation complex assembly [PMID:bio_10.1101_2025.08.12.669905]. Genetically, LBP-1a knockout mice die by embryonic day 11.5 from failed extraembryonic angiogenesis—placental labyrinthine and yolk sac vascular networks fail to form—a defect mapped to endothelial cells by tetraploid complementation (PMID:15282311).

1. 2004 High

   Establishing whether UBP1 has an essential physiological role, in vivo loss-of-function defined it as a non-redundant regulator of extraembryonic blood vessel formation.

   Evidence germline knockout mouse with placental/yolk sac histology and tetraploid complementation

   PMID:15282311

   Open questions at the time

   • The direct transcriptional targets driving the endothelial angiogenic program are not identified
   • Whether the vascular role depends on LBP-1b heterodimerization is untested
2. 2004 Medium

   To determine a molecular activity, UBP1 was shown to bind a defined promoter element and activate transcription, establishing it as a direct DNA-binding transcriptional activator at a metabolic gene.

   Evidence EMSA and luciferase reporter assays with overexpression at the CYP2A8 PREX/XRE locus

   PMID:15716014

   Open questions at the time

   • Single locus and single study
   • Cofactors mediating activation not defined
3. 2005 Medium

   Addressing how a cytosolic factor reaches its DNA targets, imaging revealed that UBP1 nuclear entry is gated by heterodimerization with the NLS-bearing splice variant LBP-1b, followed by PML body accumulation.

   Evidence YFP-fusion live-cell localization in COS-7 cells with co-expression rescue and NLS/domain deletion mapping

   PMID:16115195

   Open questions at the time

   • Functional consequence of PML body accumulation unknown
   • Whether endogenous LBP-1b stoichiometry controls UBP1 nuclear access in vivo not shown
4. 2009 High

   To define UBP1 function in the immune system, ChIP and in vivo perturbation showed it binds switch regions in an isotype-specific manner and represses class switch recombination to IgA.

   Evidence ChIP in primary B cells and bone marrow chimeric mice with isotype-specific CSR readout

   PMID:19384868

   Open questions at the time

   • Molecular mechanism of repression at S regions not resolved
   • Why occupancy is lost upon LPS stimulation is unexplained
5. 2009 Low

   Linking UBP1 to physiology, genetic mapping associated the locus with blood pressure and attributed a role in steroidogenesis via CYP11A activation.

   Evidence QTL mapping in BXD mice plus human association and functional annotation as a CYP11A activator

   PMID:19662162

   Open questions at the time

   • Direct CYP11A transcriptional activation experiment not detailed
   • Causal link between UBP1 genotype and blood pressure not mechanistically established
6. 2024 Low

   Extending UBP1 to developmental gene regulation, Xenopus assays placed it as a cofactor with Foxi1 and Dmrt2 in ionocyte specification.

   Evidence gain- and loss-of-function in Xenopus embryonic epidermis (preprint)

   PMID:bio_10.1101_2024.10.27.620464

   Open questions at the time

   • No direct biochemical characterization of Ubp1 in this program
   • Direct target genes and binding sites not defined
7. 2025 Medium

   Resolving how UBP1's activator-versus-repressor output is determined, purification and reporter assays defined a MED16-UBP1-TFCP2 subcomplex whose effect depends on motif position relative to the TSS, with TSS-overlapping binding repressing HIV-1 to enforce latency.

   Evidence protein purification/mass spectrometry, genomic binding analysis, and HIV-1 transcription reporter assays (preprint)

   PMID:bio_10.1101_2025.08.12.669905

   Open questions at the time

   • Preprint, single lab, not peer-reviewed
   • Structural basis for position-dependent switching not determined
   • Generality of the rule beyond HIV-1 and tested loci unproven

• It remains unknown how UBP1's distinct context-dependent roles—angiogenesis, CSR repression, steroidogenesis, and latency control—are coordinated by its dimerization state, cofactor availability, and promoter geometry across cell types.
• No unified model connecting LBP-1b dimerization to target selection
• Endothelial angiogenic targets unidentified
• No structural model of the UBP1-TFCP2-MED16 complex